Format

Send to

Choose Destination
Fertil Steril. 2014 Dec;102(6):1591-5.e2. doi: 10.1016/j.fertnstert.2014.08.006. Epub 2014 Sep 16.

Endometrial infusion of human chorionic gonadotropin at the time of blastocyst embryo transfer does not impact clinical outcomes: a randomized, double-blind, placebo-controlled trial.

Author information

1
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers-Robert Wood Johnson Medical School, Basking Ridge, New Jersey; Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey. Electronic address: khong@rmanj.com.
2
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers-Robert Wood Johnson Medical School, Basking Ridge, New Jersey; Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey.
3
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers-Robert Wood Johnson Medical School, Basking Ridge, New Jersey.
4
Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey.

Abstract

OBJECTIVE:

To determine whether endometrial hCG infusion at the time of human blastocyst transfer impacts implantation rates.

DESIGN:

Randomized double-blinded placebo-controlled trial.

SETTING:

Academic.

PATIENT(S):

Infertile couples with the female partner less than 43 years old (n = 300) undergoing fresh or frozen ET of one or two blastocysts.

INTERVENTION(S):

Patients undergoing ET were randomized into either a treatment or a control group. The treatment group received an infusion of 500 IU of hCG diluted in ET media. The control group received a sham infusion of ET media. Infusions were done using a separate catheter less than 3 minutes before actual ET.

MAIN OUTCOME MEASURE(S):

Sustained implantation rate: ongoing viable gestation (primary outcome) and ongoing pregnancy rate (secondary outcome).

RESULT(S):

A total of 473 blastocysts were transferred into 300 patients. There were no differences between the two groups in sustained implantation rate (48.1% in the hCG group, 44.2% in the control group) or ongoing pregnancy rate (58.8% in the hCG group, 52.0% in the control group).

CONCLUSION(S):

Endometrial infusion of hCG at the time of blastocyst ET does not improve sustained implantation rates.

CLINICAL TRIAL REGISTRATION NUMBER:

NCT01643993.

KEYWORDS:

embryo transfer; hCG; implantation rate; intrauterine hCG; pregnancy rate

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center